People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurona Therapeutics, Inc | — | Biotechnology | Series D+ | $347.5M | $874.2M | 2024 |
Ray Kelleher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ray Kelleher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Goeddel | 1 | 10 |
| Tim Kutzkey | 1 | 7 |
| Peter Svennilson | 1 | 4 |
| Leo - Guthart | 1 | 4 |
| Erica Whittaker | 1 | 3 |
| Robert Tjian | 1 | 3 |
| James Stutz | 1 | 2 |
| Brad Margus | 1 | 2 |
| Erica Whitaker | 1 | 1 |
| Arnold R. Kriegstein | 1 | 1 |
| Cory Nicholas | 1 | 1 |
| Leo R. Guthart | 1 | 1 |
| Robert R. Tijan | 1 | 1 |
| Stephen R. Hauser | 1 | 1 |
| Stephen Hauser | 1 | 1 |
| Arnold Kriegstein | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.